🚀
Enjoy a 7-Day Free Trial Thru Apr 30, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Xeris Biopharma Holdings Inc (NAS:XERS)
News
Xeris Biopharma Holdings Inc
3
NAS
:XERS (USA) Â
Ordinary Shares
$ 1.78
+0.04 (+2.3%)
10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 250.01M
Enterprise V:
$ 401.13M
Volume:
1.26M
Avg Vol (2M):
2.00M
Warning! GuruFocus detected 3 Severe warning signs with XERS.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
1.26M
Market Cap $:
250.01M
PE Ratio:
At Loss
Avg Vol (2M):
2.00M
Enterprise Value $:
401.13M
PB Ratio:
0
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Xeris Biopharma Holdings Inc (NAS:XERS) Stock News, Headlines & Updates
Xeris Biopharma Holdings Inc Stock News from GuruFocus
Total 113
1
2
3
Apr 03, 2024
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
•
4:00pm
Mar 07, 2024
Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023
GuruFocus Research
•
12:47pm
Q4 2023 Xeris Biopharma Holdings Inc Earnings Call Transcript
GuruFocus Research
•
11:03pm
Mar 06, 2024
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
Business Wire
•
7:00am
Feb 28, 2024
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
Business Wire
•
7:00am
Feb 09, 2024
Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference Transcript
GuruFocus Research
•
12:12pm
Q3 2023 Xeris Biopharma Holdings Inc Earnings Call Transcript
GuruFocus Research
•
12:12pm
Q2 2023 Xeris Biopharma Holdings Inc Earnings Call Transcript
GuruFocus Research
•
12:12pm
Q1 2023 Xeris Biopharma Holdings Inc Earnings Call Transcript
GuruFocus Research
•
12:12pm
Q4 2022 Xeris Biopharma Holdings Inc Earnings Call Transcript
GuruFocus Research
•
12:12pm
Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference Transcript
GuruFocus Research
•
12:12pm
Q3 2022 Xeris Biopharma Holdings Inc Earnings Call Transcript
GuruFocus Research
•
12:12pm
Xeris Biopharma Holdings Inc XP-8121 Call Transcript
GuruFocus Research
•
12:12pm
Q2 2022 Xeris Biopharma Holdings Inc Earnings Call Transcript
GuruFocus Research
•
12:12pm
Q1 2022 Xeris Biopharma Holdings Inc Earnings Call Transcript
GuruFocus Research
•
12:12pm
Q4 2021 Xeris Biopharma Holdings Inc Earnings Call Transcript
GuruFocus Research
•
12:12pm
Q3 2021 Xeris Biopharma Holdings Inc Earnings Call Transcript
GuruFocus Research
•
12:12pm
Jan 10, 2024
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
Business Wire
•
8:00am
Jan 05, 2024
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
•
4:00pm
Jan 04, 2024
Xeris Biopharma Updates Its Outlook for 2023
Business Wire
•
7:00am
Dec 27, 2023
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Business Wire
•
7:00am
Nov 09, 2023
Xeris Biopharma Holdings Inc (XERS) Reports Substantial Revenue Growth in Q3 2023
GuruFocus Research
•
7:10am
Oct 16, 2023
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
Business Wire
•
7:00am
Sep 27, 2023
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
Business Wire
•
8:00am
Sep 14, 2023
Xeris to Participate in the 2023 Cantor Global Healthcare Conference
Business Wire
•
4:00pm
Aug 28, 2023
Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
Business Wire
•
7:00am
Aug 08, 2023
Xeris Biopharma Reports Second Quarter 2023 Financial Results
Business Wire
•
7:00am
Aug 01, 2023
Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023
Business Wire
•
7:00am
Jul 31, 2023
Xeris Ships One Millionth Gvoke® Unit
Business Wire
•
7:00am
Nov 18, 2021
Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer
GuruFocusNews
•
8:00am
Jul 19, 2021
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe
Business Wire
•
8:00am
Jul 02, 2021
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
•
4:00pm
Jun 10, 2021
Xeris Pharmaceuticals Stock Is Estimated To Be Possible Value Trap
GF Value
•
1:00pm
Jun 05, 2021
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ALTA, XERS, ONB, FFWM; Shareholders are Encouraged to Contact the Firm
Marketwired
•
3:00pm
May 24, 2021
Xeris Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Xeris Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XERS
Business Wire
•
6:00pm
Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
Business Wire
•
7:00am
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
Business Wire
•
6:00am
May 13, 2021
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
Business Wire
•
7:00am
May 10, 2021
Xeris Pharmaceuticals to Webcast Upcoming Presentations
Business Wire
•
4:01pm
May 06, 2021
Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
Business Wire
•
4:02pm
Total 113
1
2
3
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news